CN112746034A - Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof - Google Patents
Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof Download PDFInfo
- Publication number
- CN112746034A CN112746034A CN202010958309.7A CN202010958309A CN112746034A CN 112746034 A CN112746034 A CN 112746034A CN 202010958309 A CN202010958309 A CN 202010958309A CN 112746034 A CN112746034 A CN 112746034A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- helicobacter pylori
- lactobacillus
- component
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 115
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 79
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 79
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 63
- 239000000843 powder Substances 0.000 claims abstract description 28
- 210000002784 stomach Anatomy 0.000 claims abstract description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 19
- 210000000214 mouth Anatomy 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 13
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 10
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 10
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 10
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 9
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 9
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 9
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 9
- 229940082787 spirulina Drugs 0.000 claims abstract description 9
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 6
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims description 25
- 238000004321 preservation Methods 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 6
- 239000006041 probiotic Substances 0.000 abstract description 80
- 235000018291 probiotics Nutrition 0.000 abstract description 80
- 230000000694 effects Effects 0.000 abstract description 11
- 244000005700 microbiome Species 0.000 abstract description 9
- 230000000052 comparative effect Effects 0.000 description 43
- 230000000529 probiotic effect Effects 0.000 description 38
- 241000186605 Lactobacillus paracasei Species 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 240000002605 Lactobacillus helveticus Species 0.000 description 8
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 8
- 229940054346 lactobacillus helveticus Drugs 0.000 description 8
- 241000229143 Hippophae Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of microorganisms, and provides lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof, wherein the lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 are included, the mixed probiotics is used for preparing foods for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tracts, the foods comprise a component A and a component B, and the component A is prepared from the following components in a mass ratio of 1-2: 1 of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519, wherein the component B comprises the following components in parts by weight: the hericium erinaceus powder comprises 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder, and further comprises a component C, wherein the component C is one or more of bifidobacterium, lactobacillus acidophilus and lactobacillus plantarum. By adopting the technical scheme, the problem that the composition for inhibiting the helicobacter pylori has a single effect of inhibiting the helicobacter pylori in the prior art is solved.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof.
Background
Helicobacter pylori (Hp) is a gram-negative, microaerophilic bacterium of the spiral, unipolar, and pizzled hair type, which colonizes the stomach and duodenum in various regions, and the presence of Helicobacter pylori is also detected in the oral cavity and feces of some people. Hp is closely related to various digestive system diseases, Hp infection is an important cause of various digestive tract diseases such as chronic gastritis, peptic ulcer and gastric cancer, and Hp is listed as a class I carcinogen by the world health organization.
The human body is a complex living body, and a huge number of microbial communities with complex structures exist on the body surface and the mucous membranes in the body. With the continuous development of Hp research, the oral cavity, stomach and intestinal tract of the existing part of helicobacter pylori are not only an organ which exists alone but also a symbiont of a plurality of flora closely related to each other. The oral cavity contains numerous organs, which are the alimentary canal in direct contact with the outside, and the special structure of the alimentary canal, wherein millions of various microorganisms exist, the oral cavity has obvious correlation with the HP infection of the stomach, and the dental plaque is one of the main sources of the HP reinfection of the gastric mucosa. Although under the action of gastric juice, most microorganisms are difficult to survive in the stomach. Recently, however, a wide variety of bacteria have been found in the stomach, including Proteobacteria, Bacteroides, Bacteromonas, Actinomycetes, and Clostridia. The intestine, which is the most concentrated part of human microorganisms, lives a large number of microorganisms, and has a total weight of about 1.5 kg and contains about trillion bacteria. The oral cavity and the gastrointestinal tract are the most important habitats of microbial communities, and the gastrointestinal tract microbial communities not only maintain the health of human bodies, but also participate in numerous pathophysiological processes of organisms and are closely related to pathogenesis of a plurality of diseases. The probiotics can repair the mucosa permeability of gastric mucosa, form a mucosa barrier and inhibit the adhesion of pathogenic bacteria such as H.
The treatment of helicobacter pylori is roughly divided into antibiotics, traditional Chinese medicine components, various bioactive substances, various bacteriostatic substances, microorganism preparations or various mixed preparations according to the effective components. At present, the conventional treatment of helicobacter pylori is mainly based on a quadruple therapy (a bismuth agent and a proton pump inhibitor are combined with two antibiotics), although the conventional treatment can effectively sterilize in a short time, the eradication rate is gradually reduced, the Hp drug resistance is continuously increased, in addition, the normal flora of the gastrointestinal tract is damaged, and exogenous pathogenic bacteria are fixedly planted, so that the patient is suffered from digestive tract side effects such as abdominal pain, diarrhea, abdominal distension, constipation, nausea and the like; as for the probiotic strains, it has been disclosed in the literature that probiotic strains such as Bacillus subtilis, Bacillus licheniformis, enterococcus faecalis, Bifidobacterium longum, Lactobacillus crispatus, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus salivarius have an inhibitory effect on helicobacter pylori, but the inhibitory effect of a single probiotic strain on helicobacter pylori is relatively poor.
In addition, CN02136931 discloses a biological agent for inhibiting and killing helicobacter pylori, a preparation method and application thereof, and proteins and polypeptides with a bactericidal function; CN 202010104360-discloses an anti-oral helicobacter pylori probiotic toothpaste and a preparation method thereof, which comprises three types of probiotics; CN201110179109 discloses a food composition and a pharmaceutical composition of lactobacillus strains for treating gastric ulcer; CN201811468833 discloses a composition for regulating intestinal flora and a preparation method thereof. Although the above patents provide effective single strain, mixed strain, Chinese medicinal components, various active substances and compositions for inhibiting helicobacter pylori, these compositions have relatively single effect of inhibiting helicobacter pylori, and can only inhibit helicobacter pylori in oral cavity or stomach, so it is necessary to develop a mixed probiotic which can effectively inhibit helicobacter pylori in oral cavity and stomach and improve gastrointestinal discomfort.
Disclosure of Invention
The invention provides lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof, and solves the problem that a composition for inhibiting helicobacter pylori in the prior art has a single effect of inhibiting helicobacter pylori.
The technical scheme of the invention is realized as follows:
a mixed bacterium of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori comprises lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519, wherein the preservation number of the lactobacillus rhamnosus LR863 is CGMCC No.14410, and the preservation number of the lactobacillus rhamnosus LR519 is CGMCC No. 15969.
As a further technical scheme, the mass ratio of lactobacillus rhamnosus LR863 to lactobacillus rhamnosus LR519 is 1-2: 1.
as a further technical scheme, the mass ratio of lactobacillus rhamnosus LR863 to lactobacillus rhamnosus LR519 is 1: 1.
The invention also provides application of the mixed bacteria of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting the helicobacter pylori, which is characterized by being used for preparing food for inhibiting the helicobacter pylori in oral cavity and stomach and improving intestinal tracts.
As a further technical proposal, the food comprises a component A and a component B,
the component A is prepared from the following components in a mass ratio of 1-2: 1 of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519,
the component B comprises the following components in parts by weight: 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder.
As a further technical scheme, the mass ratio of the component A to the component B is 1-3: 11.
as a further technical scheme, the food also comprises a component C, wherein the component C is one or more of bifidobacterium, lactobacillus acidophilus and lactobacillus plantarum.
As a further technical scheme, the mass ratio of the component A to the component B to the component C is 1-3: 11: (1-2).
The working principle and the beneficial effects of the invention are as follows:
1. in the invention, the component A is mixed probiotics of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519, the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 have synergistic effect, the helicobacter pylori in oral cavity and stomach can be effectively inhibited, compared with a single strain of the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519, the mixed probiotics obtained by mixing the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 according to a specific mass ratio, the inhibition effect on the helicobacter pylori is obviously improved, when the mass ratio of the lactobacillus rhamnosus LR863 to the lactobacillus rhamnosus LR519 is 1: the bacteriostatic effect is best when 1 is used.
2. In the invention, the component B comprises hericium erinaceus powder, galacto-oligosaccharide, tuckahoe powder, spirulina and sea buckthorn powder, and the hericium erinaceus powder, the tuckahoe powder, the spirulina and the sea buckthorn powder are mutually compatible, so that the gastric acid can be inhibited, the stomach mucosa activity can be improved, and the ulcer can be repaired.
3. In the invention, the component C is one or more of bifidobacterium, lactobacillus acidophilus and lactobacillus plantarum, and the component C and galactooligosaccharide are mutually cooperated, so that the probiotics is supplemented, nutrition is provided for gastrointestinal flora, the content of lactobacillus in intestinal tracts is increased, the balance of the gastrointestinal flora is maintained, and the immunity of the gastrointestinal tract is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the following examples and comparative examples, each probiotic was deposited in the China general microbiological culture Collection center (CGMCC), with the following deposit numbers:
the Lactobacillus rhamnosus LR863 is classified and named as Lactobacillus rhamnosus (Lactobacillus rhamnosus), is preserved in the common microorganism center of China Committee for culture Collection of microorganisms of China academy of sciences, has the preservation date of 2017, 07 month and 12 days, has the preservation number of CGMCC No.14410 and the preservation address of: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North;
lactobacillus rhamnosus LR519 with preservation number of CGMCC No. 15969;
the Lactobacillus paracasei 1069 is classified and named as Lactobacillus paracasei (Lactobacillus paracasei), and is preserved in the common microorganism center of the China Committee for culture Collection of microorganisms of the institute of microbiology, China academy of sciences, wherein the preservation date is 2019, 10 and 14 months, the preservation number is CGMCC No.18676, and the preservation address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North;
lactobacillus helveticus L551 with preservation number CGMCC NO. 15604;
lactobacillus plantarum LP45 with the preservation number of CGMCCNo.8072;
lactobacillus acidophilus La28 with the preservation number GMCCNo. 11506;
lactobacillus paracasei L578, accession number GMCCNo. 1560.
First, an embodiment
Example 1
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 2
A mixed probiotic for inhibiting helicobacter pylori comprises 3 mass ratios of: 2 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 3
A mixed probiotic for inhibiting helicobacter pylori comprises the following components in a mass ratio of 2: 1 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 4
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 2 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 5
A mixed probiotic for inhibiting helicobacter pylori comprises 4 mass ratios of: 1 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 6
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 4 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Example 7
A mixed probiotic for inhibiting helicobacter pylori comprises the following components in a mass ratio of 2: 3 lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR 519.
Comparative example 1
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus rhamnosus LR 863.
Comparative example 2
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus rhamnosus LR 519.
Probiotic culture of the above examples and comparative examples: inoculating the strain into a test tube containing a liquid MRS culture medium according to the inoculation amount of 1 percent, and standing and culturing for 18 hours at the temperature of 37 ℃.
Control group 1
Mixed probiotic supernatant of comparative example 1.
Control group 2
Mixed probiotic supernatant of comparative example 2.
Control group 3
Mixed probiotic supernatant of example 1.
Acquisition of probiotic supernatant in control group: respectively centrifuging the culture bacteria of example 1, comparative example 1 and comparative example 2 at 4 deg.C 10000 Xg for 3min to obtain supernatant, and filtering with 0.22 μm filter for sterilization to obtain;
taking the probiotics of the examples 1-7, the comparative examples 1-2 and the control groups 1-3 as target bacteria, the following target bacteria in-vitro bacteriostasis experiments are carried out:
after two generations of helicobacter pylori activation, 1X 10 is used8Helicobacter pylori with the concentration of CFU/mL is coated on a fresh Columbia medium blood plate without antibiotic, immediately placed into an Oxford cup, 100 mu L of each target bacterium to be detected is added, and the mixture is fixed for 1h under the microaerobic condition. After 72h of incubation, the diameter of the zone of inhibition was measured and the results are given in the following table:
TABLE 1 results of in vitro probiotic bacteria inhibition experiments in examples 1-7 and comparative examples 1-2
As can be seen from the data in table 1, compared with comparative examples 1 to 2, the mixed probiotics of examples 1 to 6 have significantly improved antibacterial effects, wherein the mixed probiotics of examples 1 to 3 have relatively better antibacterial effects, and the mixed probiotics of example 1 has the best antibacterial effects, which indicates that compared with single strains of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519, the antibacterial effects of the mixed probiotics obtained by mixing lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 are significantly improved when the specific mass ratios of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 (1: 1, 3: 2, 2: 1, 1: 2, 1: 4 and 4: 1), wherein when the mass ratios of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 are 1: 1. 3: 2. and 2: 1, the antibacterial effect is relatively good, wherein when the weight ratio of lactobacillus rhamnosus LR863 to lactobacillus rhamnosus LR519 is 1: the bacteriostatic effect is best when 1 is used. The data of the control groups 1-3 show that the bacteriostatic effect of the mixed supernatant of the lactobacillus rhamnosus LR863 and the supernatant of the lactobacillus rhamnosus LR519 is not much better than that of the single supernatant of the lactobacillus rhamnosus LR863 and the single supernatant of the lactobacillus rhamnosus LR519, which indicates that the bacteriostatic effect of the mixed supernatant of the lactobacillus rhamnosus LR863 and the supernatant of the lactobacillus rhamnosus LR519 on helicobacter pylori is not synergistic, and the mixed supernatant of the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 has a synergistic effect on helicobacter pylori. Therefore, under the condition that the total amount of probiotics is constant, the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 with specific mass ratio have the following synergistic effect, and the effect of inhibiting helicobacter pylori is obviously improved.
Comparative example 3
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus paracasei 1069.
Comparative example 4
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus helveticus L551.
Comparative example 5
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus plantarum LP 45.
Comparative example 6
A probiotic bacterium for inhibiting helicobacter pylori comprises Lactobacillus acidophilus La 28.
Comparative example 7
A probiotic for inhibiting helicobacter pylori comprises Lactobacillus paracasei L578.
Comparative example 8
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus paracasei 1069 and lactobacillus helveticus L551.
Comparative example 9
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR863 and lactobacillus paracasei 1069.
Comparative example 10
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus plantarum LP45 and lactobacillus helveticus L551.
Comparative example 11
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus acidophilus La28 and lactobacillus paracasei 1069.
Comparative example 12
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus acidophilus La28 and lactobacillus helveticus L551.
Comparative example 13
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus acidophilus La28 and lactobacillus paracasei L578.
Comparative example 14
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus paracasei 1069 and lactobacillus helveticus L551.
Comparative example 15
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR863 and lactobacillus acidophilus La 28.
Comparative example 16
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR863 and lactobacillus helveticus L551.
Comparative example 17
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR863 and lactobacillus paracasei L578.
Comparative example 18
A mixed probiotic for inhibiting helicobacter pylori comprises 1: 1 lactobacillus rhamnosus LR519 and lactobacillus paracasei 1069.
Taking the probiotics in the embodiment 1 and the comparative examples 1-18 as target bacteria, the following target bacteria in-vitro bacteriostasis experiments are carried out:
after two generations of helicobacter pylori activation, 1X 10 is used8Helicobacter pylori with the concentration of CFU/mL is coated on a fresh Columbia medium blood plate without antibiotic, immediately placed into an Oxford cup, 100 mu L of each target bacterium to be detected is added, and the mixture is fixed for 1h under the microaerobic condition. After 72h of incubation, the diameter of the zone of inhibition was measured and the results are given in the following table:
table 2 results of in vitro antibacterial experiments for probiotics in example 1 and comparative examples 1 to 18
The data in the table above show that comparative examples 1 to 7 are all single probiotics, example 1 and comparative examples 8 to 18 are all mixed probiotics, the bacteriostatic effect of the mixed probiotics of comparative examples 8 to 14 is reduced compared with that of the single probiotics in the respective mixed probiotics, the bacteriostatic effect of the mixed probiotics of comparative examples 15 to 18 is improved compared with that of the single probiotics in the respective mixed probiotics, but the bacteriostatic effect of the mixed probiotics of comparative examples 15 to 18 is poorer than that of the mixed probiotics of example 1, and the description shows that under the condition of unchanged total amount, the two probiotics with bacteriostatic effects respectively have the mass ratio of 1: 1 the mixed probiotics obtained by mixing has a better bacteriostatic effect than the original single probiotics, and in the mixed probiotics with a better bacteriostatic effect than the original single probiotics, the mixed probiotics prepared by the mass ratio of 1: 1, the mixed probiotics obtained by mixing the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 has the best effect, so that the mixed probiotics with the mass ratio of 1: the combination of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 produced unexpected effects.
And (3) taking the probiotics in the comparative examples 1-7 as target bacteria, and performing the following target bacteria hydrophobicity determination:
centrifuging the activated target bacterium suspension at 4000r/min for 10 min; collecting bacterial sludge, removing supernatant, adding 1ml PBS, blowing, sucking, mixing, and centrifuging at 4000r/min for 10 min; PBS was added to the supernatant, and the absorbance at 600nm was adjusted to 0.40 OD. Is marked as A0; according to the following steps: 1(v/v) adding a dimethylbenzene solution, shaking for 5min, standing for 1h, and taking a water phase; measuring the absorbance at 600nm by using PBS buffer as a control, and recording the value as A; the hydrophobic rate of the bacterial cell surface is calculated according to the following formula: the hydrophobicity rate is [ (a 0-a)/a 0] × 100%; the test results are given in the following table:
TABLE 3 Probiotics hydrophobicity ratios of comparative examples 1-7
| Group of | Target bacterium | Hydrophobic Rate (%) |
| Comparative example 1 | Lactobacillus rhamnosus LR863 | 81.13 |
| Comparative example 2 | Lactobacillus rhamnosus LR519 | 24.09 |
| Comparative example 3 | Lactobacillus paracasei 1069 | 62.93 |
| Comparative example 4 | Lactobacillus helveticus L551 | 29.01 |
| Comparative example 5 | Lactobacillus plantarum LP45 | 7.27 |
| Comparative example 6 | Lactobacillus acidophilus La28 | 65.20 |
| Comparative example 7 | Lactobacillus paracasei L578 | 75.82 |
As can be seen from the data in the table above, the single probiotic bacteria have the highest hydrophobic rate of Lactobacillus rhamnosus LR863, which indicates that the Lactobacillus rhamnosus LR863 has strong hydrophobic property, strong effect on gastrointestinal epithelial mucosa cells and good effect of inhibiting helicobacter pylori.
Second, application example
Application example 1
The mixed probiotics for inhibiting helicobacter pylori of example 1 is used for preparing the food for inhibiting helicobacter pylori of oral cavity and stomach and improving intestinal tract:
taking the mixed probiotics in the embodiment 1 as a component A, and mixing the component A with the component B according to the mass ratio of 1: 11, mixing to obtain the food for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tract, wherein the component B comprises the following components in parts by weight: 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder.
Application example 2
The mixed probiotics for inhibiting helicobacter pylori of the example 2 is used for preparing the food for inhibiting helicobacter pylori of oral cavity and stomach and improving intestinal tract:
taking the mixed probiotics in the embodiment 2 as a component A, and mixing the component A with the component B according to the mass ratio of 3: 11, mixing to obtain the food for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tract, wherein the component B comprises the following components in parts by weight: 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder.
Application example 3
The mixed probiotics for inhibiting helicobacter pylori of the example 3 is used for preparing the food for inhibiting helicobacter pylori of the oral cavity and the stomach and improving the intestinal tract:
taking the mixed probiotics in the embodiment 3 as a component A, and mixing the component A with the component B and the component C according to the mass ratio of 1: 11: 1, obtaining the food for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tract, wherein the component B comprises the following components in parts by weight: 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina, 20 parts of sea buckthorn powder and component C of bifidobacterium.
Application example 4
The mixed probiotics for inhibiting helicobacter pylori of example 1 is used for preparing the food for inhibiting helicobacter pylori of oral cavity and stomach and improving intestinal tract:
taking the mixed probiotics in the embodiment 1 as a component A, and mixing the component A with the component B and the component C according to the mass ratio of 1: 11: 2, mixing and mixing to obtain the food for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tract, wherein the food comprises 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder, and the component C comprises bifidobacterium, lactobacillus acidophilus and lactobacillus plantarum.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions, improvements, etc. within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The mixed bacteria of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori are characterized by comprising lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519, wherein the preservation number of the lactobacillus rhamnosus LR863 is CGMCC No.14410, and the preservation number of the lactobacillus rhamnosus LR519 is CGMCC No. 15969.
2. The mixed bacterium of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori according to claim 1, wherein the mass ratio of lactobacillus rhamnosus LR863 to lactobacillus rhamnosus LR519 is 1-2: 1.
3. the mixed bacterium of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori according to claim 2, wherein the mass ratio of lactobacillus rhamnosus LR863 to lactobacillus rhamnosus LR519 is 1: 1.
4. the application of the mixed bacteria of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori according to any one of claims 1 to 3, wherein the mixed bacteria are used for preparing foods for inhibiting helicobacter pylori in oral cavity and stomach and improving intestinal tracts.
5. The use of a mixture of Lactobacillus rhamnosus LR863 and Lactobacillus rhamnosus LR519 for synergistic inhibition of helicobacter pylori according to claim 4, wherein the food product comprises component A and component B,
the component A is prepared from the following components in a mass ratio of 1-2: 1 of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519,
the component B comprises the following components in parts by weight: 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea buckthorn powder.
6. The application of the mixed bacteria of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori according to claim 5, wherein the mass ratio of the component A to the component B is 1-3: 11.
7. the use of a mixture of lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for the synergistic inhibition of helicobacter pylori according to claim 6, characterized in that said food further comprises component C, said component C being one or more of bifidobacterium, lactobacillus acidophilus, lactobacillus plantarum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958309.7A CN112746034B (en) | 2020-09-14 | 2020-09-14 | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010958309.7A CN112746034B (en) | 2020-09-14 | 2020-09-14 | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112746034A true CN112746034A (en) | 2021-05-04 |
| CN112746034B CN112746034B (en) | 2022-07-29 |
Family
ID=75645716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010958309.7A Active CN112746034B (en) | 2020-09-14 | 2020-09-14 | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112746034B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662192A (en) * | 2021-08-02 | 2021-11-19 | 石家庄君乐宝乳业有限公司 | Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof |
| CN114392281A (en) * | 2022-01-28 | 2022-04-26 | 河北一然生物科技股份有限公司 | New application of lactobacillus acidophilus La28 for inhibiting helicobacter pylori in gastric mucosa protection product |
| CN114404458A (en) * | 2022-01-12 | 2022-04-29 | 诺佰克（武汉）生物科技有限公司 | Application of lactobacillus paracasei nbk-LC16 in improvement of helicobacter pylori infection and preparation of anti-inflammatory stomach-protecting product |
| CN114958658A (en) * | 2022-05-11 | 2022-08-30 | 广西爱生生命科技有限公司 | Lactobacillus rhamnosus A21149 and application thereof |
| CN116333945A (en) * | 2023-05-12 | 2023-06-27 | 成都海若健康科技有限公司 | Helicobacter pylori resistant lactobacillus rhamnosus PUK09 and application, product and method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101314763A (en) * | 2007-06-01 | 2008-12-03 | 统一企业(中国)投资有限公司 | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction |
| US7858336B1 (en) * | 2010-02-01 | 2010-12-28 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
| CN108048347A (en) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | Lactobacillus rhamnosus, lactobacillus rhamnosus preparation and application thereof |
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| TW202007401A (en) * | 2018-07-20 | 2020-02-16 | 景岳生物科技股份有限公司 | Lactic acid bacteria composition used to inhibit gastritis caused by Helicobacter pylori, H. pylori and use thereof characterized by achieving the effect of inhibiting multi-drug resistant Helicobacter pylori and antibiotic sensitive Helicobacter pylori |
| CN111607538A (en) * | 2020-05-29 | 2020-09-01 | 江南大学 | Lactobacillus rhamnosus and application thereof in inhibiting helicobacter pylori |
-
2020
- 2020-09-14 CN CN202010958309.7A patent/CN112746034B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101314763A (en) * | 2007-06-01 | 2008-12-03 | 统一企业(中国)投资有限公司 | Short bifidobacteria with functions of anti-gastrointestinal tract pathogen, oxidation resistance and blood pressure reduction |
| US7858336B1 (en) * | 2010-02-01 | 2010-12-28 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
| CN108048347A (en) * | 2017-12-06 | 2018-05-18 | 河北然生物科技有限公司 | Lactobacillus rhamnosus, lactobacillus rhamnosus preparation and application thereof |
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| TW202007401A (en) * | 2018-07-20 | 2020-02-16 | 景岳生物科技股份有限公司 | Lactic acid bacteria composition used to inhibit gastritis caused by Helicobacter pylori, H. pylori and use thereof characterized by achieving the effect of inhibiting multi-drug resistant Helicobacter pylori and antibiotic sensitive Helicobacter pylori |
| CN111607538A (en) * | 2020-05-29 | 2020-09-01 | 江南大学 | Lactobacillus rhamnosus and application thereof in inhibiting helicobacter pylori |
Non-Patent Citations (1)
| Title |
|---|
| 李君怡等: "防制幽门螺杆菌的人源益生菌的筛选及抑菌机理研究", 《第14届益生菌与健康国际研讨会》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113662192A (en) * | 2021-08-02 | 2021-11-19 | 石家庄君乐宝乳业有限公司 | Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof |
| CN114404458A (en) * | 2022-01-12 | 2022-04-29 | 诺佰克（武汉）生物科技有限公司 | Application of lactobacillus paracasei nbk-LC16 in improvement of helicobacter pylori infection and preparation of anti-inflammatory stomach-protecting product |
| CN114404458B (en) * | 2022-01-12 | 2024-01-19 | 诺佰克（武汉）生物科技有限公司 | Application of lactobacillus paracasei nbk-LC16 in improving helicobacter pylori infection and preparing anti-inflammatory and stomach-protecting products |
| CN114392281A (en) * | 2022-01-28 | 2022-04-26 | 河北一然生物科技股份有限公司 | New application of lactobacillus acidophilus La28 for inhibiting helicobacter pylori in gastric mucosa protection product |
| CN114958658A (en) * | 2022-05-11 | 2022-08-30 | 广西爱生生命科技有限公司 | Lactobacillus rhamnosus A21149 and application thereof |
| CN114958658B (en) * | 2022-05-11 | 2023-08-11 | 广西爱生生命科技有限公司 | Lactobacillus rhamnosus A21149 for inhibiting helicobacter pylori and application thereof |
| CN116333945A (en) * | 2023-05-12 | 2023-06-27 | 成都海若健康科技有限公司 | Helicobacter pylori resistant lactobacillus rhamnosus PUK09 and application, product and method thereof |
| CN116333945B (en) * | 2023-05-12 | 2023-08-01 | 成都海若健康科技有限公司 | Helicobacter pylori resistant lactobacillus rhamnosus PUK09 and application, product and method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112746034B (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112746034B (en) | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof | |
| CN100378214C (en) | Probiotic bacterium: lactobacillus fermentum | |
| TWI574633B (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| JP5830084B2 (en) | Method of using Bacillus subtilis strains for the prevention and treatment of gastrointestinal conditions | |
| EP0760848A1 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
| CN112210516B (en) | Lactobacillus helveticus L1258 with intestinal regulation function and composition thereof | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
| KR102617297B1 (en) | Composition for Treatment or Prevention of Clostridium Difficile Infection | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
| JP4509250B2 (en) | Helicobacter pylori sanitizing medicine | |
| CN116396884A (en) | Lactobacillus rhamnosus and a composition for inhibiting helicobacter pylori | |
| CN114836349A (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN114806953A (en) | Lactobacillus gasseri with characteristic of improving type 1 diabetes | |
| CN109536424A (en) | A kind of Lactobacillus brevis and its application | |
| CN109517765A (en) | A kind of streptococcus fecalis and its application | |
| CN116790402B (en) | Bacteroides simplex strain with anti-inflammatory property, culture method and application | |
| CN114574405B (en) | Lactobacillus plantarum WKA86, application thereof in preparation of halitosis preventing and treating product and halitosis preventing and treating product | |
| CN116731913B (en) | Application of lactobacillus plantarum in preparation of helicobacter pylori resistant products | |
| CN117106628B (en) | Lactobacillus acidophilus LA15 with immunoregulation capability and application, product and method thereof | |
| JPH03120222A (en) | Adjuvant | |
| CN117004538B (en) | Lactobacillus reuteri and application thereof | |
| CN116103197B (en) | Streptococcus thermophilus with helicobacter pylori inhibiting effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: 050899 No. 16, bangxiu East Road, North District, Zhengding high tech Industrial Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |